Stocks and Investing Stocks and Investing
Fri, November 10, 2017
Thu, November 9, 2017

David Lebovitz Maintained (ALNY) at Hold with Increased Target to $130 on, Nov 9th, 2017


Published on 2024-10-26 00:50:42 - WOPRAI, David Lebovitz
  Print publication without navigation


David Lebovitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Increased Target from $101 to $130 on, Nov 9th, 2017.

David has made no other calls on ALNY in the last 4 months.



There are 9 other peers that have a rating on ALNY. Out of the 9 peers that are also analyzing ALNY, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Paul Matteis of "Leerink Swann" Maintained at Hold with Increased Target to $112 on, Thursday, September 21st, 2017


These are the ratings of the 8 analyists that currently disagree with David


  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $158 on, Wednesday, November 8th, 2017
  • Madhu Kumar of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $220 on, Wednesday, November 8th, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $151 on, Friday, November 3rd, 2017
  • Rahul Jasuja of "FBR Capital" Maintained at Strong Buy with Increased Target to $240 on, Thursday, November 2nd, 2017
  • Terence Flynn of "Goldman Sachs" Upgraded from Hold to Strong Buy on, Monday, October 2nd, 2017
  • Do Kim of "BMO Capital" Maintained at Buy with Increased Target to $134 on, Friday, September 22nd, 2017
  • Alan Carr of "Needham" Maintained at Strong Buy with Increased Target to $125 on, Thursday, September 21st, 2017
  • Christopher Marai of "Nomura" Initiated at Sell and Held Target at $56 on, Friday, September 15th, 2017
Contributing Sources